Safety and Feasibility of S-1 Adjuvant Chemotherapy for Gastric Cancer in Elderly Patients

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2011 Jul 1

PMID 21717091

Citations 9

Authors

Toru Aoyama

Takaki Yoshikawa

Takafumi Watanabe

Tsutomu Hayashi

Takashi Ogata

Haruhiko Cho

Akira Tsuburaya

Affiliations

Soon will be listed here.

Abstract

Background: The safety and feasibility of administering S-1 adjuvant chemotherapy for gastric cancer has not been fully evaluated in elderly patients.

Methods: This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed with stage II or III disease, and received adjuvant S-1 at our institution. Patients were categorized into two groups; non-elderly patients (age <70 years: group A) and elderly patients (age ≥70 years: group B). The toxicity and S-1 continuation rates in the two groups were compared.

Results: A total of 75 patients were evaluated in the study. There were no grade 4 toxicities. The incidences of grade 3 hematological and non-hematological toxicities were <5% in both groups, and the differences were not significant. The continuation rate at 6 months was 69% in group A and 70% in group B, and this difference was also not significant.

Conclusions: These results suggest that S-1 adjuvant chemotherapy for gastric cancer is safe and feasible, regardless of the age of the patient; especially for elderly patients who could be candidates for clinical trials.

Citing Articles

Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer.

Hirahara N, Matsubara T, Kaji S, Hayashi H, Kawakami K, Sasaki Y BMC Cancer. 2022; 22(1):718.

PMID: 35768866 PMC: 9245214. DOI: 10.1186/s12885-022-09827-3.

National Underutilization of Neoadjuvant Chemotherapy for Gastric Cancer.

Liu N, Xu Y, Rahnemai-Azar A, Abbott D, Weber S, Lidor A J Gastrointest Surg. 2019; 24(4):949-958.

PMID: 31792901 PMC: 7486798. DOI: 10.1007/s11605-019-04439-y.

Underutilization of Treatment for Regional Gastric Cancer Among the Elderly in the USA.

Liu N, Molena D, Stem M, Blackford A, Sewell D, Lidor A J Gastrointest Surg. 2018; 22(6):955-963.

PMID: 29404983 PMC: 5983904. DOI: 10.1007/s11605-018-3691-3.

A long-surviving case of gastric cancer with main portal vein tumor thrombus after surgical resection and postoperative S-1 therapy.

Sato S, Nagai E, Taki Y, Watanabe M, Takahashi M, Kyoden Y Clin J Gastroenterol. 2016; 9(4):233-7.

PMID: 27318995 DOI: 10.1007/s12328-016-0665-4.

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.

Jeong J, Park S, Ahn Y, Ryu M, Ryoo B, Kong S Gastric Cancer. 2015; 20(1):146-155.

PMID: 26715117 DOI: 10.1007/s10120-015-0586-9.

References

Bonadonna G, Valagussa P . Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304(1):10-5. DOI: 10.1056/NEJM198101013040103. View

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K . Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999; 5(8):2000-5. View

Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M . Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. Cancer Chemother Pharmacol. 2007; 61(2):335-43. DOI: 10.1007/s00280-007-0595-4. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View

Tsushima T, Hironaka S, Boku N, Machida N, Yamazaki K, Yasui H . Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer. Gastric Cancer. 2010; 13(4):245-50. DOI: 10.1007/s10120-010-0566-z. View

Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y . A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. Jpn J Clin Oncol. 2005; 35(11):672-5. DOI: 10.1093/jjco/hyi179. View

Yancik R, Ries L . Cancer in older persons. Magnitude of the problem--how do we apply what we know?. Cancer. 1994; 74(7 Suppl):1995-2003. DOI: 10.1002/1097-0142(19941001)74:7+<1995::aid-cncr2820741702>3.0.co;2-y. View

10.

Tatsumi K, Fukushima M, Shirasaka T, Fujii S . Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 1987; 78(7):748-55. View

11.

Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K . Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996; 7(5):548-57. DOI: 10.1097/00001813-199607000-00010. View

12.

Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359(5):453-62. DOI: 10.1056/NEJMoa0707035. View